HCPCS Level IIdrugActive
J2351
Inj ocrelizumab 1mg hya-ocsq
BETOS: O1E
Effective: 2025-04-01
Description
Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Ocrevus Zunovo
Manufacturer
Genentech, Inc.
HCPCS Dosage
1 MG
Billing Units
920.0000
1
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.